Piper Sandler upgraded Intra-Cellular (ITCI) to Overweight from Neutral with a price target of $92, up from $68. The firm says feedback from its survey of 25 psychiatrists was suggestive of a patient and prescription volume footprint for Caplyta as adjunctive treatment for major depressive disorder that is similar to the one that AbbVie (ABBV) is carving out for Vraylar in this setting. Piper now believes Caplyta’s peak sales can approach or exceed $4B. This makes for a “fundamentally more benign risk/reward profile” for Intra-Cellular shares, even when considering the uncertainty associated with Caplyta’s exclusivity runway, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular upgraded to Overweight from Neutral at Piper Sandler
- Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
- Intra-Cellular price target raised to $81 from $79 at JPMorgan
- Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
- Intra-Cellular price target raised to $130 from $120 at Cantor Fitzgerald